An interventional study of Hemopatch and Tachosil in Air Leak From Lung, sponsored by Baxter Healthcare Corporation. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-06.
Sponsored by Baxter Healthcare Corporation · Not applicable, Interventional, and Treatment
This study is a randomized, controlled study, with the primary objective to demonstrate non-inferiority of Hemopatch compared to TachoSil in postoperative air leak duration after pulmonary resection, and with the secondary objective of evaluating the safety of Hemopatch compared to TachoSil.
Preoperative-
Intraoperative-
Exclusion Criteria:
Preoperative-
Intraoperative-
Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
Device: Hemopatch
Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
Device: Tachosil
Applied according to the current instruction for use (IFU). According to the IFU, a maximum of 7 Hemopatch 45 x 90 mm patches can be used in adults.
Applied according to the current instruction for use (IFU).
Duration of postoperative air leakage
Time frame: Day 1 to Day 30
Incidence of intraoperative treatment failure
Time frame: Day 1
Incidence of patients with prolonged air leakage defined as air leakage > 5 Days
Time frame: Day 5 to Day 30
Number of additional procedures needed
Type of procedures include chest drainage, re-operation, respiratory assistance, and blood transfusion
Time frame: Day 1 to Day 30
Time to chest tube removal
Time frame: Day 1 to Day 30
Time in surgery (minutes) from incision to closure
Time frame: Day 1
Length of stay in hospital (days)
Time frame: Day 1 to Day 30
Number of unplanned interventions
Time frame: Day 1 to Day 30
Incidence of pre-defined postoperative Adverse Events of Special Interest (AESIs)
Pre-defined AEs include Pneumothorax, Bronchopleural fistula, Emphysema (subcutaneous and mediastinal), Pleural effusions, Postoperative respiratory failure, Empyema, Allergic reactions in reasonable temporal relationship with the product application
Time frame: Day 1 to Day 30
Number of patches used intra-operatively
Time frame: Day 1
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Baxter Healthcare Corporation